CN115397998A - 由天然或合成dna产生的基于痘病毒的载体及其用途 - Google Patents

由天然或合成dna产生的基于痘病毒的载体及其用途 Download PDF

Info

Publication number
CN115397998A
CN115397998A CN202180025623.2A CN202180025623A CN115397998A CN 115397998 A CN115397998 A CN 115397998A CN 202180025623 A CN202180025623 A CN 202180025623A CN 115397998 A CN115397998 A CN 115397998A
Authority
CN
China
Prior art keywords
dna
sequence
fragments
poxvirus
smva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180025623.2A
Other languages
English (en)
Chinese (zh)
Inventor
唐·J·戴蒙德
费利克斯·乌索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN115397998A publication Critical patent/CN115397998A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180025623.2A 2020-02-03 2021-02-02 由天然或合成dna产生的基于痘病毒的载体及其用途 Pending CN115397998A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062969628P 2020-02-03 2020-02-03
US62/969,628 2020-02-03
US202063113803P 2020-11-13 2020-11-13
US63/113,803 2020-11-13
PCT/US2021/016247 WO2021158565A2 (en) 2020-02-03 2021-02-02 Poxvirus-based vectors produced by natural or synthetic dna and uses thereof

Publications (1)

Publication Number Publication Date
CN115397998A true CN115397998A (zh) 2022-11-25

Family

ID=77200801

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180025623.2A Pending CN115397998A (zh) 2020-02-03 2021-02-02 由天然或合成dna产生的基于痘病毒的载体及其用途

Country Status (10)

Country Link
EP (1) EP4100514A4 (https=)
JP (1) JP2023512294A (https=)
KR (1) KR20220148823A (https=)
CN (1) CN115397998A (https=)
AU (2) AU2021217073A1 (https=)
BR (1) BR112022014738A2 (https=)
CA (1) CA3168836A1 (https=)
IL (1) IL294926A (https=)
MX (1) MX2022009200A (https=)
WO (1) WO2021158565A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119506355A (zh) * 2025-01-15 2025-02-25 中国人民解放军军事科学院军事医学研究院 一种用于重组痘病毒包装的载体系统及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103231A4 (en) 2020-02-14 2024-03-27 Geovax, Inc. VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
JP2024505274A (ja) 2021-02-02 2024-02-05 ゲオバックス インコーポレイテッド ワクチン接種中のｔ細胞プライミングの強化において使用されるウイルスコンストラクト
CN115433741A (zh) * 2022-06-23 2022-12-06 广西大学 盖他病毒为载体表达报告蛋白的重组病毒的构建方法
CN118240879A (zh) * 2023-11-01 2024-06-25 上海市重大传染病和生物安全研究院 骨架质粒、重组质粒以及猴痘病毒颗粒和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213452A1 (en) * 2018-05-02 2019-11-07 David Evans Synthetic chimeric vaccinia virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019213452A1 (en) * 2018-05-02 2019-11-07 David Evans Synthetic chimeric vaccinia virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIDEYUKI NAKANISHI: "Comparison of piggyBac transposition efficiency between linear and circular donor vectors in mammalian cells", JOURNAL OF BIOTECHNOLOGY, 26 May 2011 (2011-05-26) *
李继东: "重组山羊痘病毒通用转移载体的构建", 中国兽医学报, 31 December 2016 (2016-12-31), pages 3 - 1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119506355A (zh) * 2025-01-15 2025-02-25 中国人民解放军军事科学院军事医学研究院 一种用于重组痘病毒包装的载体系统及其应用
CN119506355B (zh) * 2025-01-15 2025-10-17 中国人民解放军军事科学院军事医学研究院 一种用于重组痘病毒包装的载体系统及其应用

Also Published As

Publication number Publication date
WO2021158565A2 (en) 2021-08-12
KR20220148823A (ko) 2022-11-07
IL294926A (en) 2022-09-01
WO2021158565A3 (en) 2021-09-16
BR112022014738A2 (pt) 2022-10-11
EP4100514A4 (en) 2024-06-12
AU2021217073A1 (en) 2022-08-18
JP2023512294A (ja) 2023-03-24
MX2022009200A (es) 2023-01-04
AU2025287330A1 (en) 2026-01-22
CA3168836A1 (en) 2021-08-12
EP4100514A2 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
KR102357051B1 (ko) 신규 유전자 재조합 백시니아 바이러스
KR102700586B1 (ko) Hbv 백신
AU2017353868B2 (en) Synthetic chimeric poxviruses
KR102243727B1 (ko) 유전자 표적화 및 형질 스태킹을 위한 조작된 트랜스진 통합 플랫폼 (etip)
AU2013312198B2 (en) Fluorescence activated cell sorting (FACS) enrichment to generate plants
TWI902763B (zh) 基於重組痘病毒之抗SARS-CoV-2病毒疫苗
KR20210132003A (ko) 변형된 오르토폭스 바이러스 벡터
AU2019262149B2 (en) Synthetic chimeric vaccinia virus
CN115397998A (zh) 由天然或合成dna产生的基于痘病毒的载体及其用途
CN114555793B (zh) 基于基因i177l缺失的新型非洲猪瘟减毒活疫苗的开发
KR20230113832A (ko) 키메라 폭스바이러스 조성물 및 이의 용도
KR20150043540A (ko) Fad3 성능 유전자좌 및 표적화 파단을 유도할 수 있는 상응하는 표적 부위 특이적 결합 단백질
JP2026041921A (ja) 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン
KR101234062B1 (ko) 림프구 내 유전자 도입용 재조합 바이러스 벡터
CN111107872A (zh) 有用于癌症免疫疗法的牛痘病毒突变体
AU2017313450B2 (en) Viral vaccines
CN116670153A (zh) 允许在稳定细胞系中高效生长的非洲猪瘟疫苗的基因组缺失
CN110546252A (zh) 具有广泛基因组对称的mva相关的新型痘苗病毒载体
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
HK40078138A (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
HK40095569A (zh) 基於重组痘病毒的抗sars-cov-2病毒疫苗
HK40042130A (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40100707A (zh) 允许在稳定细胞系中高效生长的非洲猪瘟疫苗的基因组缺失
HK40047064A (en) Synthetic chimeric vaccinia virus
HK40076151B (zh) 基於基因i177l缺失的新型非洲猪瘟减毒活疫苗的开发

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078138

Country of ref document: HK